How has NewAmsterdam Pharma Company's change in deferred revenue changed year-over-year?

NewAmsterdam Pharma Company's change in deferred revenue decreased by 33.0% year-over-year, from -$2.28M to -$3.03M.

What does change in deferred revenue mean?

Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.

Regeneron PharmaceuticalsREGN

$99.6M+463%

Revenue$3.0M+2.1%

Operating income-$58.4M+15.2%

Net income-$48.4M-22.6%

EPS (diluted)-$0.40-17.6%

Cash & equivalents$457.6M-38.9%

Total debt$23.0K-94.1%

Total equity$665.2M-14.4%

Total assets$732.6M-10.5%

Operating cash flow-$30.6M+16.1%

CapEx$38.0K+138%

Free cash flow-$30.6M+16.0%

Market cap$3.67B+63.7%

Operating margin-953.6%-3,536pp

Net margin-942.8%-3,477pp

FCF margin-630.1%-6,324pp

Return on equity-29.5%-1.8pp

Current ratio9.8×-10.2×

Reported directly by NewAmsterdam Pharma Company in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: NewAmsterdam Pharma Company’s 10-Q, filed August 6, 2025, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is NewAmsterdam Pharma Company's change in deferred revenue?: NewAmsterdam Pharma Company (NAMS) reported change in deferred revenue of -$3.03M in Q2 2025.
How has NewAmsterdam Pharma Company's change in deferred revenue changed year-over-year?: NewAmsterdam Pharma Company's change in deferred revenue decreased by 33.0% year-over-year, from -$2.28M to -$3.03M.
What does change in deferred revenue mean?: Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.